Jill Feldman, Co-Founder of EGFR Resister, shared a post on X about recent paper by Maxime Borgeaud et al., published in CA: A Cancer Journal for Clinicians.
“Behind every biomarker is a person.
It was an honor to co-author this comprehensive review on optimizing treatment for EGFRm NSCLC.
It isn’t easy for a patient/advocate to contribute meaningfully to long, technical articles, but that’s exactly why it’s so important that we do.
This work reflects collaboration and respect. A huge thanks to the authors for valuing the patient perspective.”
Title: Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management
Authors: Maxime Borgeaud, Timothée Olivier, Jair Bar, Stephanie Pei Li Saw, Kaushal Parikh, Giuseppe Luigi Banna, Claudio De Vito, Jill Feldman, Xiuning Le, Alfredo Addeo
Read The Full Article at CA: A Cancer Journal for Clinicians.
More posts featuring Jill Feldman on OncoDaily.